QX002N
Ankylosing Spondylitis
Phase 2Active
Key Facts
About Qyuns Therapeutics
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
View full company profileTherapeutic Areas
Other Ankylosing Spondylitis Drugs
| Drug | Company | Phase |
|---|---|---|
| IL-17A/F Inhibitor (CSPC-2232) | CSPC Pharmaceutical Group Limited | Phase III |